(Q34552742)

3 August 2017

title

Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome (English)

1 reference

3 August 2017

0 references

1 reference

irritable bowel syndrome

1 reference

William D Chey

1 reference

3 August 2017

William Y Chey

1 reference

3 August 2017

Amy T Heath

1 reference

3 August 2017

George E Dukes

1 reference

3 August 2017

Eric G Carter

1 reference

3 August 2017

Allison Northcutt

1 reference

3 August 2017

Vanessa Z Ameen

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

The American Journal of Gastroenterology

3 August 2017

published in

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

page(s)

2195-2203

1 reference

AGA technical review on irritable bowel syndrome

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30509.X

The epidemiology of irritable bowel syndrome in North America: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30509.X

Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30509.X

Sexual Dysfunction in Patients with Irritable Bowel Syndrome and Non-Ulcer Dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30509.X

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30509.X

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30509.X

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30509.X

Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30509.X

Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30509.X

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30509.X

Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30509.X

Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2004.30509.X

10.1111/J.1572-0241.2004.30509.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference